Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.
Jump to:

Scancell Holdings Fundamentals

Company Name Scancell Holdings Last Updated 11 Aug 2020
Industry Health Care Sector Biotechnology
Shares in Issue (m) 465.36 Market Cap (£m) 32.34
PE Ratio -4.79 Div per Share () 0.00
Div Yield 0.00 Div Cover 0.00
EPS -1.45 EPS Growth (%) -8.21
PEG 0.58 DPS Growth (%) n/a
Debt Ratio 0.00 Debt Equity Ratio 0.00
Net Gearing -31.82 Gross Gearing 11.43
Asset Equity Ratio 1.13 Cash Equity Ratio 48.83
Quick Ratio 5.87 Current Ratio 5.87
Price To Book Value 3.46 ROCE -71.92

Scancell Holdings Dividends

Type Ex-Date Pay Date Currency Net Dividend Year Total

Scancell Holdings Company Financials

Assets (£m) 2019 2018 2017
Tangible Assets 0 0 0
Intangible Assets 3 3 3
Investments 0 0 0
Total Fixed Assets 3 3 4
Stocks 0 0 0
Debtors 1 0 0
Cash & Equivalents 5 10 3
Other Assets 2 1 1
Total Assets 11 15 7
Liabilities (£m) 2019 2018 2017
Creditors within 1 year 1 1 1
Creditors after 1 year 0 0 0
Other Liabilities 0 0 0
Total Liabilities 1 1 1
Net assets 9 14 7
Equity (£m) 2019 2018 2017
Called up share capital 0 0 0
Share Premium 35 33 22
Profit / Loss -7 -5 -5
Other Equity 0 1 1
Preference & Minorities 0 0 0
Total Capital Employed 9 14 7
Ratios 2019 2018 2017
Debt Ratio 0.00 0.00 0.00
Debt-to-Equity 0.00 0.00 0.00
Net Gearing -31.82 -65.64 -30.44
Gross Gearing 11.43 4.76 7.57
Assets / Equity 1.13 1.05 1.08
Cash / Equity 48.83 73.90 41.11
EPS -1.45 -1.34 -1.36
Cash Flow (£m) 2019 2018 2017
Cash from operating activities -7 -4 -4
Cashflow before financing -7 -4 -4
Increase in Cash -6 8 -4
Income (£m) 2019 2018 2017
Turnover 0 0 0
Cost of sales 0 0 0
Gross Profit 0 0 0
Operating Profit -7 -5 -5
Pre-Tax profit -7 -5 -5
Profit / Loss for the year 0 0 0

Scancell Holdings Company Background

Sector Biotechnology
Activities Scancell Holdings plc is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody and Moditope technology platforms. Scancell's first ImmunoBody, SCIB1 is being developed for the treatment of melanoma. Data from the Phase 1/2 clinical trial demonstrate that SCIB1, when used as monotherapy, has a marked effect on tumour load, produces a melanoma-specific immune response and highly encouraging survival trend without serious side effects. In patients with resected disease there is increasing evidence to suggest that SCIB1 may delay or prevent disease recurrence. Scancell's ImmunoBody vaccines target dendritic cells and stimulate both parts of the cellular immune system: the helper cell system where inflammation is stimulated at the tumour site, and the cytotoxic T-lymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells. Pre-clinical data on a combination of SCIB1 or SCIB2 and checkpoint inhibition (blockade of the PD-1 or CTLA-4 immune checkpoint pathways) have shown enhanced tumour destruction and significantly longer survival times than when either treatment was used alone. Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4+ T cells that have the ability to destroy tumours with minimal toxicity. The Directors believe that the Moditope platform could play a major role in the development of safe and effective cancer immunotherapies in the future.
Latest Interim Date 31 Jan 2020
Latest Fiscal Year End Date 20 Aug 2019

Scancell Holdings Directors

Appointed Director Position
2018-01-10 Dr Clifford Michael Holloway Chief Executive Officer
2008-04-15 Prof Linda Gillian Durrant Chief Scientific Officer
2008-04-15 Dr Richard Morley Goodfellow Executive Director
2014-05-01 Dr Sally Elizabeth Adams Executive Director
2015-10-14 Dr John Chiplin Non-Executive Chairman
2019-10-23 Dr Ursula Mary Ney Non-Executive Director
2016-08-22 Dr Alan James Lewis Non-Executive Director
2019-06-18 Martin Henry Diggle Non-Executive Director

Scancell Holdings Contact Details

Company Name Scancell Holdings
Company Address City Hospital, Hucknall Road, Nottingham NG5 1PB.
Company Telephone +44 (0)115 823 1863
Company Website http://www.scancell.co.uk/

Scancell Holdings Advisors

Auditor Name Champion Accountants
Auditor Address 2nd Floor, Refuge House, 33-37 Watergate Row, Chester CH1 2LE.
Auditor Website http://www.champion-accountants.co.uk/
Auditor Telephone +44 (0)1244 404 420
Registrar Name SLC Registrars Ltd
Registrar Address 42-46 High Street, Esher KT10 9QY.
Registrar Website http://www.davidvenus.com/
Registrar Telephone +44 (0)1372 467 308
Broker Name Cenkos Securities Limited
Broker Address 6.7.8. Tokenhouse Yard, London EC2R 7AS.
Broker Website http://www.cenkos.com/
Broker Telephone +44 (0)20 7397 8900
Adviser Name Cenkos Securities Limited
Adviser Address 6.7.8. Tokenhouse Yard, London EC2R 7AS.
Adviser Website http://www.cenkos.com/
Adviser Telephone +44 (0)20 7397 8900
Solicitor Name Laytons
Solicitor Address Carmelite, 50 Victoria Embankment, Blackfriars, London EC4Y 0LS.
Solicitor Website http://www.laytons.com/
Solicitor Telephone +44 (0)20 7842 8000
Stockbroker Name n/a
Stockbroker Address n/a
Stockbroker Website n/a
Stockbroker Telephone n/a